Xinfeng capsule for the treatment of rheumatoid arthritis patients with decreased pulmonary function--a randomized controlled clinical trial.
- Author:
Lei WAN
1
;
Jian LIU
2
;
Chuan-bing HUANG
1
;
Yuan WANG
1
;
Xi CHEN
1
;
Wan-dong ZHANG
1
;
Gui-zhen WANG
1
;
Hai-xia FAN
1
;
Yao GE
1
;
Rui-lian CHEN
1
;
Yun-xiang CAO
1
;
Rui-kai ZONG
1
;
Tian-yang LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: Xinfeng Capsule; clinical trial; pulmonary function; quality of life; rheumatoid arthritis
- MeSH: Adult; Aged; Arthritis, Rheumatoid; blood; drug therapy; pathology; physiopathology; Blood Sedimentation; C-Reactive Protein; Capsules; Drugs, Chinese Herbal; therapeutic use; Female; Humans; Joints; pathology; Male; Middle Aged; Quality of Life; Respiratory Function Tests; Surveys and Questionnaires; Treatment Outcome
- From: Chinese journal of integrative medicine 2016;22(3):168-176
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo determine the effectiveness and safety of Xinfeng Capsules (XFC) for the treatment of rheumatoid arthritis (RA) patients with decreased pulmonary function.
METHODSThis was a randomized controlled clinical trial of 80 RA patients. Participants were assigned to the trial group (40 cases) and the control group (40 cases) by block randomization. The trial group was treated with XFC, three pills each time three times daily for 2 months. The control group was treated with tripterygium glycoside (TPT), two pills each time three times daily for 2 months. Both groups were followed up after 2 months. The clinical effects, changes in joint and pulmonary function, and quality of life before and after treatment were observed; safety indices were also evaluated.
RESULTSPain, swelling, tenderness, and duration of morning stiffness of joints were obviously decreased after treatment in both the trial and the control groups compared with baseline (P<0.01). Compared with before treatment, hand grip strength increased significantly after treatment in the trial group (P=0.0000); pulmonary function parameters such as forced expiratory volume in the first second of expiration/forced vital capacity (FEV1/FVC), 50% of the expiratory flow of forced vital capacity (FEF50), carbon monoxide diffusing capacity (DLco) were increased (P<0.01 or P<0.05); measures of quality of life such as role-physical, body pain, vitality and mental health were also improved after treatment in the trial group (all P<0.05). Joint swelling in the trial group decreased compared with the control group (P=0.0043), while hand grip strength was increased after treatment (P=0.0000). The increase in FEF50, DLco, and the dimensions of quality of life such as vitality and mental health were all significantly greater in the trial group than the control group (P<0.05 or P<0.01).
CONCLUSIONSXFC not only relieved joint pain in RA patients, but also significantly improved the ventilation and diffusion function of the lungs. Therefore, XFC could improve the whole body function and enhance the quality of life of RA patients.
